CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Treadwell Therapeutics Clinical Trials
- Phone Number: +1-416-455-7510
- Email: clinicaltrials@treadwelltx.com
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- START San Antonio
-
-
Utah
-
West Valley City, Utah, United States, 84119
- START - Mountain Region
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialist
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Part A Escalation
1. Have histological or cytological proof of advanced cancer that has progressed on at least 1 prior line of systemic therapy
Inclusion Criteria: Part A Expansion
- Breast cancer patients positive for estrogen receptor and/or progesterone receptor and negative for HER2
- Must have previously received a CDK4/6 inhibitor
- No limit on lines of endocrine therapy
- Must have received no more than 1 line of cytotoxic chemotherapy
- Have measurable disease as per RECIST 1.1 guidelines.
Inclusion Criteria: Part B
- Breast cancer patients positive for estrogen receptor and/or progesterone receptor and negative for HER2
- Must have previously received a CDK4/6 inhibitor
- Must have previously received no more than 1 line of endocrine therapy
- Must have received no more than 1 line of cytotoxic chemotherapy
- Have measurable disease as per RECIST 1.1 guidelines.
Exclusion Criteria: All Parts
- Are pregnant or nursing.
- Have received chemotherapy, biological therapy, or investigational treatment less than 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug. Have received radiotherapy less than 2 weeks prior to first dose of study drug.
- Received growth factors within 14 days prior to initiation of dosing of CFI-402257 or who will require ongoing treatment with growth factors
- Have active, acute, or clinically significant chronic infections.
Have the following cardiovascular conditions
- Have uncontrolled severe hypertension
- Have symptomatic congestive heart failure
- Have active angina pectoris or recent myocardial infarction
- Have chronic atrial fibrillation or QTc of greater than 470 msec.
- Have had major surgery within 21 days of starting therapy.
- Primary central nervous system malignancies or known central nervous system metastasis.
- Being treated with full dose warfarin.
- Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism.
- Patients must avoid the use of strong CYP3A4 inducers and inhibitors. CYP3A sensitive substrates, PgP, BCRP inhibitors
- Have had prior treatment with a TTK/MPS1 inhibitor.
- Part B only: Known bleeding disorder which would prohibit administration of fulvestrant.
- Part B only: Concomitant active malignancy other than ER+/HER2- advanced breast cancer.
- Part A only: Concomitant active malignancy other than primary malignancy
- Part B only: Had prior treatment with fulvestrant or agents with similar MoA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: Monotherapy Escalation and Expansion
Dose selection and expansion of CFI-402257
|
Oral once daily in 28 day cycles
Other Names:
|
|
Experimental: Part B: Combination Escalation and Expansion
Dose selection and expansion of CFI-402257 with Fulvestrant
|
Oral once daily in 28 day cycles
Other Names:
500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the incidence of adverse events of CFI-402257 as a single agent and at the recommended phase 2 dose (RP2D)
Time Frame: 48 months
|
The number of subjects who experience an adverse event that was possibly related to study drug as assessed by CTCAE v 5.0.
|
48 months
|
|
To assess the incidence of adverse events of CFI-402257 in combination with fulvestrant and at the recommended phase 2 dose (RP2D)
Time Frame: 48 months
|
The number of subjects who experience an adverse event that was possibly related to study drug as assessed by CTCAE v 5.0.
|
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of objective response rates
Time Frame: 48 months
|
Objective response rate will be summarized by dose cohort and overall using the percent of patients in each tumor response category.
|
48 months
|
|
Assessment of objective response rates of the combination
Time Frame: 48 months
|
Objective response rate will be summarized overall for advanced breast cancer patients
|
48 months
|
|
Assessment of the pharmacokinetic profile of CFI-402257 through AUC
Time Frame: 48 months
|
Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.
|
48 months
|
|
Assessment of the pharmacokinetic profile of CFI-402257 in combination with fulvestrant through AUC
Time Frame: 48 months
|
Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.
|
48 months
|
|
To evaluate the effect of CFI-402257 treatment on changes in variant allele function
Time Frame: 48 months
|
Changes in variant allele function will be measured by looking at circulating tumor deoxyribonucleic acid compared to baseline
|
48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: R Wesolowski, The Ohio State University Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TWT-203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.